(Press-News.org) A new study has demonstrated no significant benefit of taking the drug bosentan for idiopathic pulmonary fibrosis (IPF).
The results were published online ahead of the print edition in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. Read the full study here.
Although the primary endpoint of the Bosentan Use in Interstitial Lung Disease (BUILD)-3 study was not attained, researchers point to the possibility of benefit for a subset of IPF patients who had undergone surgical lung biopsy to confirm their diagnosis. The study, however, had insufficient power to confirm this finding.
"The effects of the drug were not great enough to detect with statistical significance in the population that we examined," said lead author of the study, Talmadge King, Jr., chair of the Department of Medicine at the University of California, San Francisco. "While these results are certainly not what we had wanted, we did find reasons to hope that we may yet demonstrate that bosentan does a have a beneficial effect in a select group of IPF sufferers."
Three years ago, Dr. King and colleagues conducted the BUILD-1 trial, a prospective, double-blind, placebo-controlled trial designed to determine whether bosentan could improve six-minute walk distances in IPF patients after one year. That trial failed to demonstrate a difference in six-minute walk distances, but a post-hoc analysis suggested that patients who underwent surgical lung biopsy to confirm their IPF diagnosis had improvements in their health-related quality of life and delayed worsening of their IPF.
The BUILD-3 trial was designed to refine the patient population that appeared to benefit from bosentan in BUILD-1 and assess the effects of the drug more precisely. The randomized, double-blind placebo-controlled study enrolled a total of more than 600 patients were enrolled and randomized 2:1 to receive bosentan or a placebo. Patients were eligible if they had mild to moderate IPF, confirmed by surgical lung biopsy, for three years or less. Patients with extensive honeycombing (indicating more advanced disease) were excluded.
Each patient was assessed at baseline, at randomization, and every four months thereafter until the conclusion on the study. The primary endpoint of the study was IPF worsening or all-cause death. IPF worsening was defined as a decrease of at least 10 percent in forced vital capacity and at least 15 percent in the DLCO, confirmed by tests four weeks apart.
Secondary endpoints included changes in health-related quality of life, time to IPF worsening and time to death.
The patients were followed for a mean of 19.9 months until the end of the study, which was predetermined to be when 202 IPF-related "events"—that is, worsening or death—occurred. There was no significant difference between treatment and placebo groups for time to death or to IPF worsening.
"This outcome was very disappointing," said Dr. King. "We have long believed that treatment of patients with early disease would stack the deck in favor of any potentially effective therapy for IPF. That did not happen in this study."
Health-related quality of life scores were also not significantly different between groups. There was a small, non-significant delay to time of IPF worsening up to End of Study (excluding death) between patients receiving bosentan and those on placebo. There was also non-significant evidence of a positive effect of bosentan on loss of lung function as measured by FVC and DLCO.
"This study was rigorously designed to elucidate the effect suggested by BUILD-1," said Dr. King. "Unfortunately, despite the rigorous and clinically important endpoints, we were unable to demonstrate the expected results. However, there is hope that endothelin antagonists, alone or in combinations with other anti-fibrotic agents, can benefit a certain subpopulation of people with IPF; our goal moving forward to is to identify that population more precisely."
"Although this was a negative study, these investigators continue to move us toward finding effective treatments for IPF, primarily because they have advanced our understanding of how to design rigorous clinical trials for IPF, which has been extremely difficult to study," said John E. Heffner, MD, past president of the American Thoracic Society. "As these investigative approaches are applied to other potential drug therapies, we anticipate it is only a matter of time until we discover ways to improve the course of patients with IPF."
INFORMATION: END
VIDEO:
This is a video of a "beating " cardiomyocyte.
Click here for more information.
Johns Hopkins scientists have developed a simplified, cheaper, all-purpose method they say can be used by scientists around the globe to more safely turn blood cells into heart cells. The method is virus-free and produces heart cells that beat with nearly 100 percent efficiency, they claim.
"We took the recipe for this process from a complex minestrone to a simple miso soup," ...
LA JOLLA, CA – New research by scientists at The Scripps Research Institute and collaborating institutions has identified a key regulator of fat cell development that may provide a target for obesity and diabetes drugs.
In a paper published in the latest issue of Cell Metabolism, the scientists describe a protein called TLE3 that acts as a dual switch to turn on signals that stimulate fat cell formation and turn off those that keep fat cells from developing. TLE3 works in partnership with a protein that is already the target of several diabetes drugs, but their use has ...
Does a reduction in the price of alcohol result in an increase in deaths due to alcohol? This was the subject of a study following a significant reduction in taxes in Finland in 2004 (30% for spirits, 3% for wine).The abolition of import quotas by the EU in 2004 also made it possible to import from other member countries and this led to an increase of approximately 10% in alcohol consumption in Finland. This paper is particularly interesting as it not only reports the effects of reducing costs of alcohol on alcohol-related mortality, but it also reports the effects of such ...
PHILADELPHIA — The advancements of our electronic age rests on our ability to control how electric charge moves, from point A to point B, through circuitry. Doing so requires particular precision, for applications ranging from computers, image sensors and solar cells, and that task falls to semiconductors.
Now, a research team at the University of Pennsylvania's schools of Engineering and Applied Science and Arts and Sciences has shown how to control the characteristics of semiconductor nanowires made of a promising material: lead selenide.
Led by Cherie Kagan, professor ...
ARLINGTON, Va. - Marking a milestone for the Navy, the Office of Naval Research and its industry partner on April 6 successfully tested a solid-state, high-energy laser (HEL) from a surface ship, which disabled a small target vessel.
The Navy and Northrop Grumman completed at-sea testing of the Maritime Laser Demonstrator (MLD), which validated the potential to provide advanced self-defense for surface ships and personnel by keeping small boat threats at a safe distance.
"The success of this high-energy laser test is a credit to the collaboration, cooperation and teaming ...
For those old enough to remember Mutual of Omaha's "Wild Kingdom" television series, the dynamics of predator-prey relationships seemed clear enough: predators thinned out prey populations, which enabled a smaller, but stronger, population to survive and reproduce.
However, a new paper by University of Notre Dame biologist Gary Belovsky appearing in the prestigious journal Ecology Letters suggests that predator-prey relationships are much more complex than originally thought.
The paper arose out of pioneering studies Belovsky, who also is director of the Notre Dame ...
College Park, Md.—Nearly 5 million American children participate in the Boy Scouts and Girl Scouts, but until now no one has looked at the gender messages young people get when they start collecting those coveted badges.
Kathleen Denny, a sociology graduate student at the University of Maryland, College Park, analyzed scouting manuals and found that—despite positive aspects—today's scouts are being fed stereotypical ideas about femininity and masculinity. Her findings were recently published in Gender & Society, the highly-ranked journal of Sociologists for Women in Society.
Girl ...
ST. LOUIS – Saint Louis University researchers have identified a novel mechanism to control the traffic of cells and fluid from tissues to lymphatic vessels. It may be possible to harness this mechanism to fight cancer spread from one organ to another organ and improve the effectiveness of vaccines.
The lymphatic system is an extensive fluid transit system, consisting of vessels in the body. It defends the body against infection. Cancer cells and infection-fighting cells that are part of the immune system use the lymphatic system to get to other organs, including the ...
TORONTO, On – April 8, 2011 – Increased levels of a protein that helps regulate the body's blood pressure may also predict a major cardiovascular event in high-risk patients, according to a study led by St. Michael's Hospital's cardiovascular surgeon Subodh Verma. Measuring the amount of the protein, known as plasma renin activity (PRA), in the blood stream may give doctors another tool to assess a patient's risk and help prevent a heart attack or stroke.
"Conventional factors like genetics and environment do not always provide a complete patient story and an understanding ...
A galaxy's core is a busy place, crowded with stars swarming around an enormous black hole. When galaxies collide, it gets even messier as the two black holes spiral toward each other, merging to make an even bigger gravitational monster.
Once it is created, the monster goes on a rampage. The merger kicks the black hole into surrounding stars. There it finds a hearty meal, shredding and swallowing stars at a rapid clip. According to new research by Nick Stone and Avi Loeb (Harvard-Smithsonian Center for Astrophysics), upcoming sky surveys might offer astronomers a way ...
